Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment

MLA

Mouadh Barbirou, et al. “Interleukin-17A Polymorphisms Predict the Response and Development of Tolerance to FOLFOX Chemotherapy in Colorectal Cancer Treatment.” Cancer Gene Therapy, vol. 27, May 2019, pp. 311–18. EBSCOhost, https://doi.org/10.1038/s41417-019-0102-1.

APA

Mouadh Barbirou, Mouna Stayoussef, Balkiss Bouhaouala, Amel Mezlini, Wassim Y. Almawi, Amina Mokrani, Besma Yacoubi-Loueslati, Sinda A. Bedoui, & Meriem Dallel. (2019). Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment. Cancer Gene Therapy, 27, 311–318. https://doi.org/10.1038/s41417-019-0102-1

Chicago

Mouadh Barbirou, Mouna Stayoussef, Balkiss Bouhaouala, Amel Mezlini, Wassim Y. Almawi, Amina Mokrani, Besma Yacoubi-Loueslati, Sinda A. Bedoui, and Meriem Dallel. 2019. “Interleukin-17A Polymorphisms Predict the Response and Development of Tolerance to FOLFOX Chemotherapy in Colorectal Cancer Treatment.” Cancer Gene Therapy 27 (May): 311–18. doi:10.1038/s41417-019-0102-1.